Inhibitors of<unk><unk> <unk> , also DPP-4 inhibitors or gliptins, are anti-diabetic drugs and a class of oral hypoglycemics that block DPP-4. They can be used to treat diabetes mellitus type 2.
The first agent of the class - sitagliptin  - was approved by the FDA in 2006.
Glucagon increases blood glucose levels, and DPP-4 inhibitors reduce glucagon and blood glucose levels. The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.
DPP-4 inhibitors may reduce mortality when used for treating diabetes mellitus type 2.
Dipeptidyl peptidase-4 inhibitor
Renin inhibitor
Protein kinase inhibitor
Phosphodiesterase inhibitors
COX-2 inhibitor
Direct thrombin inhibitor
Angiotensin II receptor antagonist
Direct Xa inhibitor